Published in Methods Mol Med on January 01, 2006
The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr Neuropharmacol (2007) 1.32
Candidate genes for cannabis use disorders: findings, challenges and directions. Addiction (2009) 1.31
Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS One (2008) 1.26
Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann N Y Acad Sci (2008) 1.12
Depression-resistant endophenotype in mice overexpressing cannabinoid CB(2) receptors. Br J Pharmacol (2010) 1.10
A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss. Life Sci (2010) 1.04
CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity. J Psychopharmacol (2011) 1.02
Behavioral effects of CB2 cannabinoid receptor activation and its influence on food and alcohol consumption. Ann N Y Acad Sci (2008) 0.93
Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction. Pharmacol Ther (2013) 0.92
Commentary: Functional Neuronal CB2 Cannabinoid Receptors in the CNS. Curr Neuropharmacol (2011) 0.90
A possible role for the endocannabinoid system in the neurobiology of depression. Clin Pract Epidemiol Ment Health (2007) 0.87
Brain CB₂ Receptors: Implications for Neuropsychiatric Disorders. Pharmaceuticals (Basel) (2010) 0.76
Design and evaluation of a novel fluorescent CB2 ligand as probe for receptor visualization in immune cells. Bioorg Med Chem Lett (2011) 0.76
Genetic variation in FAAH is associated with cannabis use disorders in a young adult sample of Mexican Americans. Drug Alcohol Depend (2016) 0.75
Brain-derived neurotrophic factor and obesity in the WAGR syndrome. N Engl J Med (2008) 2.91
Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res (2006) 2.62
Rodent BDNF genes, novel promoters, novel splice variants, and regulation by cocaine. Brain Res (2005) 2.34
Pooled association genome scanning for alcohol dependence using 104,268 SNPs: validation and use to identify alcoholism vulnerability loci in unrelated individuals from the collaborative study on the genetics of alcoholism. Am J Med Genet B Neuropsychiatr Genet (2006) 2.09
Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci (2006) 2.07
Pooled association genome scanning: validation and use to identify addiction vulnerability loci in two samples. Proc Natl Acad Sci U S A (2005) 2.00
Addiction molecular genetics: 639,401 SNP whole genome association identifies many "cell adhesion" genes. Am J Med Genet B Neuropsychiatr Genet (2006) 1.95
Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. Mol Med (2010) 1.83
Association between genetic variants on chromosome 15q25 locus and objective measures of tobacco exposure. J Natl Cancer Inst (2012) 1.83
Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. J Neurosci (2003) 1.63
Human brain derived neurotrophic factor (BDNF) genes, splicing patterns, and assessments of associations with substance abuse and Parkinson's Disease. Am J Med Genet B Neuropsychiatr Genet (2005) 1.60
Neurexin 3 polymorphisms are associated with alcohol dependence and altered expression of specific isoforms. Hum Mol Genet (2007) 1.56
Linkage disequilibrium, haplotype and association studies of a chromosome 4 GABA receptor gene cluster: candidate gene variants for addictions. Am J Med Genet B Neuropsychiatr Genet (2006) 1.51
Reduced behavioral effects of cocaine in heterozygous brain-derived neurotrophic factor (BDNF) knockout mice. Neuropsychopharmacology (2003) 1.48
Human dopamine transporter gene variation: effects of protein coding variants V55A and V382A on expression and uptake activities. Pharmacogenomics J (2003) 1.42
Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters. Neuropsychopharmacology (2004) 1.41
Dramatically decreased cocaine self-administration in dopamine but not serotonin transporter knock-out mice. J Neurosci (2009) 1.33
A human-specific de novo protein-coding gene associated with human brain functions. PLoS Comput Biol (2010) 1.31
CHRNA3 rs1051730 genotype and short-term smoking cessation. Nicotine Tob Res (2011) 1.31
Genome-wide association for nicotine dependence and smoking cessation success in NIH research volunteers. Mol Med (2008) 1.27
Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS One (2008) 1.26
NrCAM in addiction vulnerability: positional cloning, drug-regulation, haplotype-specific expression, and altered drug reward in knockout mice. Neuropsychopharmacology (2006) 1.24
Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletions. Behav Pharmacol (2008) 1.23
How individual sensitivity to opiates can be predicted by gene analyses. Trends Pharmacol Sci (2005) 1.22
Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia. Pharmacogenet Genomics (2008) 1.18
Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice. Neuropsychopharmacology (2004) 1.15
Risk analysis for invasive species: general framework and research needs. Risk Anal (2004) 1.15
Postsynaptic localization of CB2 cannabinoid receptors in the rat hippocampus. Synapse (2008) 1.13
Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann N Y Acad Sci (2008) 1.12
Genome wide association for substance dependence: convergent results from epidemiologic and research volunteer samples. BMC Med Genet (2008) 1.12
Genomewide high-density SNP linkage analysis of 236 Japanese families supports the existence of schizophrenia susceptibility loci on chromosomes 1p, 14q, and 20p. Am J Hum Genet (2005) 1.11
Risk assessment for invasive species. Risk Anal (2004) 1.11
Involvement of SMARCA2/BRM in the SWI/SNF chromatin-remodeling complex in schizophrenia. Hum Mol Genet (2009) 1.11
Mu opioid receptor-dependent and independent components in effects of tramadol. Neuropharmacology (2006) 1.09
SLC18A2 promoter haplotypes and identification of a novel protective factor against alcoholism. Hum Mol Genet (2005) 1.08
Personalized medicine and opioid analgesic prescribing for chronic pain: opportunities and challenges. J Pain (2013) 1.06
Common human 5' dopamine transporter (SLC6A3) haplotypes yield varying expression levels in vivo. Cell Mol Neurobiol (2006) 1.05
Bromocriptine administration reduces hyperphagia and adiposity and differentially affects dopamine D2 receptor and transporter binding in leptin-receptor-deficient Zucker rats and rats with diet-induced obesity. Neuroendocrinology (2008) 1.05
Genome wide association for addiction: replicated results and comparisons of two analytic approaches. PLoS One (2010) 1.04
CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity. J Psychopharmacol (2011) 1.02
Genome-wide association for smoking cessation success: participants in a trial with adjunctive denicotinized cigarettes. Mol Med (2009) 1.02
Norepinephrine transporter blockade can normalize the prepulse inhibition deficits found in dopamine transporter knockout mice. Neuropsychopharmacology (2006) 1.01
OKCAM: an ontology-based, human-centered knowledgebase for cell adhesion molecules. Nucleic Acids Res (2008) 1.01
Genomic regions identified by overlapping clusters of nominally-positive SNPs from genome-wide studies of alcohol and illegal substance dependence. PLoS One (2011) 1.00
Molecular mechanisms underlying the rewarding effects of cocaine. Ann N Y Acad Sci (2004) 1.00
Methamphetamine-induced hyperthermia and lethal toxicity: role of the dopamine and serotonin transporters. Eur J Pharmacol (2007) 1.00
mu-Opioid receptor knockout mice display reduced cocaine conditioned place preference but enhanced sensitization of cocaine-induced locomotion. Brain Res Mol Brain Res (2004) 1.00
Phosphatidylinositol 3-kinase, protein kinase C, and MEK1/2 kinase regulation of dopamine transporters (DAT) require N-terminal DAT phosphoacceptor sites. J Biol Chem (2003) 1.00
Active behaviours produced by antidepressants and opioids in the mouse tail suspension test. Int J Neuropsychopharmacol (2012) 0.99
Convergent genome wide association results for bipolar disorder and substance dependence. Am J Med Genet B Neuropsychiatr Genet (2009) 0.99
Dopamine transporter mutants with cocaine resistance and normal dopamine uptake provide targets for cocaine antagonism. Mol Pharmacol (2002) 0.98
KEPI, a PKC-dependent protein phosphatase 1 inhibitor regulated by morphine. J Biol Chem (2002) 0.96
Endocannabinoids and cannabinoid receptor genetics. Prog Neurobiol (2002) 0.95
Supplementing high-density SNP microarrays for additional coverage of disease-related genes: addiction as a paradigm. PLoS One (2009) 0.94
A polymorphism of the metabotropic glutamate receptor mGluR7 (GRM7) gene is associated with schizophrenia. Schizophr Res (2008) 0.94
The interaction of methylphenidate and benztropine with the dopamine transporter is different than other substrates and ligands. Biochem Pharmacol (2005) 0.94
Implications of genome wide association studies for addiction: are our a priori assumptions all wrong? Pharmacol Ther (2013) 0.93
dextro- and levo-morphine attenuate opioid delta and kappa receptor agonist produced analgesia in mu-opioid receptor knockout mice. Eur J Pharmacol (2006) 0.93
Reduced emotional and corticosterone responses to stress in mu-opioid receptor knockout mice. Neuropharmacology (2009) 0.92
Monoallelic and unequal allelic expression of the HTR2A gene in human brain and peripheral lymphocytes. Biol Psychiatry (2006) 0.92
Meta-analysis and genome-wide interpretation of genetic susceptibility to drug addiction. BMC Genomics (2011) 0.91
Mu (mu) opioid receptor regulation of ethanol-induced dopamine response in the ventral striatum: evidence of genotype specific sexual dimorphic epistasis. Biol Psychiatry (2007) 0.91
Impaired spatial working memory and decreased frontal cortex BDNF protein level in dopamine transporter knockout mice. Eur J Pharmacol (2009) 0.91
Synaptic plasticity alterations associated with memory impairment induced by deletion of CB2 cannabinoid receptors. Neuropharmacology (2013) 0.91
A low chronic ethanol exposure induces morphological changes in the adolescent rat brain that are not fully recovered even after a long abstinence: an immunohistochemical study. Exp Neurol (2006) 0.90
Deletion of v7-3 (SLC6A15) transporter allows assessment of its roles in synaptosomal proline uptake, leucine uptake and behaviors. Brain Res (2007) 0.90
Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav (2009) 0.90
Methamphetamine-induced locomotor activity and sensitization in dopamine transporter and vesicular monoamine transporter 2 double mutant mice. Psychopharmacology (Berl) (2007) 0.90
Impaired cliff avoidance reaction in dopamine transporter knockout mice. Psychopharmacology (Berl) (2013) 0.89
"Replicated" genome wide association for dependence on illegal substances: genomic regions identified by overlapping clusters of nominally positive SNPs. Am J Med Genet B Neuropsychiatr Genet (2010) 0.89
Mouse brain gene expression changes after acute and chronic amphetamine. J Neurochem (2003) 0.89
The 5HT1A receptor agonist, 8-OH-DPAT, protects neurons and reduces astroglial reaction after ischemic damage caused by cortical devascularization. Brain Res (2004) 0.88
Food-reinforced operant behavior in dopamine transporter knockout mice: enhanced resistance to extinction. Ann N Y Acad Sci (2004) 0.88
Fine mapping of calcineurin (PPP3CA) gene reveals novel alternative splicing patterns, association of 5'UTR trinucleotide repeat with addiction vulnerability, and differential isoform expression in Alzheimer's disease. Subst Use Misuse (2010) 0.88
Neuronal mdr-1 gene expression after experimental focal hypoxia: a new obstacle for neuroprotection? J Neurol Sci (2007) 0.88
Neuronal and glial alterations due to focal cortical hypoxia induced by direct cobalt chloride (CoCl2) brain injection. Neurotox Res (2009) 0.87